| Complications associated with combined use of abciximab and an intracoronary thrombolytic agent (urokinase or tissue-type plasminogen activator). | |
| | |
MedLine Citation:
|
PMID: 9723644 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A potent platelet inhibitor combined with an intracoronary thrombolytic agent is aggressive therapy that may be used for high-risk, complex, refractory thrombotic coronary lesions. A retrospective review of the records of 56 patients who received abciximab plus an intracoronary thrombolytic agent during a coronary interventional procedure did not reveal a prohibitive incidence of major bleeding with this combination therapy. |
| | |
Authors:
|
R A Yaryura; M Zaqqa; J J Ferguson |
Related Documents
:
|
2646894 - Thrombolytic agents in early myocardial infarction. 16911924 - Successful thrombolytic therapy for bilateral renal infarction: a case report. 9447334 - The gusto trial and the open artery theory. 9169894 - Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. 19408074 - Use of levosimendan in patients with ischemic heart disease following mechanical reperf... 9565514 - Dobutamine stress echocardiography in anomalous left coronary artery. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The American journal of cardiology Volume: 82 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 1998 Aug |
Date Detail:
|
Created Date: 1998-09-16 Completed Date: 1998-09-16 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 518-9 Citation Subset: AIM; IM |
Affiliation:
|
Department of Cardiology, St. Luke's Episcopal Hospital/Texas Heart Institute, Houston, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Angioplasty, Transluminal, Percutaneous Coronary* Antibodies, Monoclonal / adverse effects* Coronary Disease / drug therapy*, therapy Drug Therapy, Combination Female Humans Immunoglobulin Fab Fragments / adverse effects* Male Middle Aged Plasminogen Activators / adverse effects* Platelet Aggregation Inhibitors / adverse effects* Postoperative Hemorrhage / chemically induced* Retrospective Studies Tissue Plasminogen Activator / adverse effects Urokinase-Type Plasminogen Activator / adverse effects |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; 143653-53-6/abciximab; EC 3.4.21.-/Plasminogen Activators; EC 3.4.21.68/Tissue Plasminogen Activator; EC 3.4.21.73/Urokinase-Type Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Predictive value of C-reactive protein after successful coronary-artery stenting in patients with st...
Next Document: Dipyridamole-dobutamine stress with Tc-99m sestamibi tomographic myocardial perfusion imaging.